DANBURY, Conn., July 24 /PRNewswire-FirstCall/ -- Biodel Inc. today announced that it will issue its third quarter fiscal 2007 financial results on Monday, July 30, 2007 after the market closes. Following the issuance of its financial results, Biodel’s senior management team will host a conference call to discuss the results.
July 30, 2007 Schedule: After the market closes Q3 2007 results will be distributed by PR Newswire 4:20 p.m. EDT To participate in the conference call, dial 1-800-475-3716 (United States) or 1-719-457-2728 (International) 4:30 p.m. EDT Conference call begins promptly
The conference call, including the question and answer session, is expected to last approximately half an hour.
Interested parties may access a live audio webcast of the conference call in the investor section of Biodel’s website at http://www.biodel.com. The audio webcast will be archived and available for replay 14 days following the event.
About Biodel Inc.
Biodel Inc. is a development stage specialty biopharmaceutical company located in Danbury, Connecticut. The Company is focused on the development and commercialization of innovative treatments for endocrine disorders, such as diabetes and osteoporosis. Biodel develops product candidates by applying proprietary formulation technologies to existing drugs in order to improve their therapeutic results. The Company has two insulin product candidates currently in clinical trials for the treatment of diabetes. Additionally, the Company has two preclinical product candidates for the treatment of osteoporosis.
Safe Harbor
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, including statements regarding our strategy, future operations, future financial position, future revenues, projected costs, prospects, plans and objectives of management are forward- looking statements. The words “anticipates,” “believes,” “could,” “estimates,” “expects,” “intends,” “may,” “plans,” “potential,” “predicts,” “projects,” “should,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The Company’s forward-looking statements are subject to a number of known and unknown risks and uncertainties that could cause actual results, performance or achievements to differ materially from those described or implied in the forward-looking statements, including, but not limited to, our ability to secure FDA approval for our product candidates under Section 505(b)(2) of the Federal Food, Drugs and Cosmetic Act; our ability to market, commercialize and achieve market acceptance for product candidates developed using our VIAdel(TM) technology; the progress or success of our research, development and clinical programs, the initiation and completion of our clinical trials, the timing of the interim analyses and the timing or success of our product candidates, particularly VIAject(TM) and VIAtab(TM); our ability to secure patents for VIAject(TM) and our other product candidates; our ability to protect our intellectual property and operate our business without infringing upon the intellectual property rights of others; our estimates of future performance; our ability to enter into collaboration arrangements for the commercialization of our product candidates and the success or failure of those collaborations after consummation, if consummated; the rate and degree of market acceptance and clinical utility of our products; our commercialization, marketing and manufacturing capabilities and strategy; our estimates regarding anticipated operating losses, future revenues, capital requirements and our needs for additional financing; and other factors identified in our Quarterly Report on Form 10-Q for the quarter ended March 31, 2007. The Company disclaims any obligation to update any forward-looking statements as a result of events occurring after the date of this press release.
BIOD-G
Biodel Inc.
CONTACT: Investors, Clay A. Kramer, ckramer@burnsmc.com, or Media, CarneyNoensie, cnoensie@burnsmc.com, both of Burns McClellan, Inc.,+1-212-213-0006, for Biodel Inc.
Web site: http://www.biodel.com/